Table 3.
Clinical trial of combination obinutuzumab with other new agents
| Clinical trial | Phase | Population | Regimen | Status |
|---|---|---|---|---|
| NCT02242942 | 3 | Untreated CLL | O+ABT-199 vs O+CLB | Active |
| NCT02950051 | 2 | Untreated CLL | FCR/BR or ABT-199+R or ABT-199+O or ABT-199+R+O | Recruiting |
| NCT01685892 | 1b | Relapsed/refractory CLL or untreated CLL | O+ABT-199 | Active |
| NCT02264574 | 3 | Untreated CLL | Ibrutinib reduces obinutuzumab infusion related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels+O vs O+Chl | Active |
| NCT02427451 | 1b/2 | Relapsed/refractory CLL or untreated CLL | ABT-199+O+lbrutinib | Recruiting |
| NCT02315768 | 1/2 | Untreated CLL | O+lbrutinib | Active |
| NCT02475681 | 3 | Elderly and unfit adult patients with first-line CLL | ACP-196+O or Chl+ACP-196+O | Active |
| NCT02296918 | 1 | Relapsed/refractory CLL or untreated CLL | ACP-196+O | Active |
| NCT02968563 | 2 | Relapsed/refractory CLL | Tirabrutinib+ldelalisb+O | Active |
| NCT01644253 | 1b | Relapsed/refractory CLL or untreated CLL | TRU-016+R vs TRU-016+O | Active |
| NCT02100852 | 1 | CLL (no defined) | TGR-1202+Chl+O | Active |
| NCT01644253 | 1b | Relapsed/refractory CLL or untreated CLL | TRU-016+R vs TRU-016+O | Active |
| NCT02225275 | 2 | Relapsed/refractory CLL | O+L | Active |
| NCT02401503 (CLL2-BAG) | 2 | First-line/relapsed/refractory CLL | B→O/ABT-199 | Active |
| NCT02445131 (CLL2-BCG) | 2 | Relapsed/refractory/First-line/CLL | B→O+ldelalisb | Active |
|
NCT02758665 (CLL2-Give) |
2 | Untreated CLL with TP53 deletion (17p-) and/or mutation | ABT-199+Ibrutinib+O | Active |
| NCT02983617 | 2 | Relapsed or refractory CLL | Tirabrutinib+Entospletinib+O vs Tirabrutinib+Entospletinib | Active |
| NCT02612311 | 3 | CLL | Ublituximab+TRG-1202 vs O+Chl | Active |
| NCT02320487 | 2 | Untreated CLL | B+O | Completed |
| NCT03755947 | 2 | First and second line for patients with CLL | Ibrutinib+O+ABT-199 | Recruiting |
| NCT03529227 | – | CLL with certain comorbidities | O+Chl | Active |
| NCT03462719 | 3 | Untreated CLL | Ibrutinib+ABT-199 vs O+Chl | Active |
| NCT03701282 | 3 | Untreated younger patients with CLL | Ibrutinib+O+ABT-199 vs Ibrutinib+O | Recruiting |
| NCT03737981 | 3 | Older people with untreated CLL | Ibrutinib+O+ABT-199 vs Ibrutinib+O | Recruiting |
| NCT03516617 | 2 | Early stage CLL | ACP-196+O | Recruiting |
Abbreviations: B, bendamustine; BTKi, Bruton tyrosine kinase inhibitor; Chl, chlorambucil; CLL, chronic lymphocytic leukemia; FC, fludarabine plus cyclophosphamide; L, lenalidomide; PI3Ki, phosphatidylinositol-3 kinase inhibitor; R, rituximab; O, obinutuzumab.